JP2017501141A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501141A5
JP2017501141A5 JP2016536571A JP2016536571A JP2017501141A5 JP 2017501141 A5 JP2017501141 A5 JP 2017501141A5 JP 2016536571 A JP2016536571 A JP 2016536571A JP 2016536571 A JP2016536571 A JP 2016536571A JP 2017501141 A5 JP2017501141 A5 JP 2017501141A5
Authority
JP
Japan
Prior art keywords
dimethoxy
hours
dihydroisoquinoline
water
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536571A
Other languages
English (en)
Japanese (ja)
Other versions
JP6542222B2 (ja
JP2017501141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/067117 external-priority patent/WO2015084622A1/en
Publication of JP2017501141A publication Critical patent/JP2017501141A/ja
Publication of JP2017501141A5 publication Critical patent/JP2017501141A5/ja
Application granted granted Critical
Publication of JP6542222B2 publication Critical patent/JP6542222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536571A 2013-12-03 2014-11-24 ベンゾキノリン化合物の製造方法 Active JP6542222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911214P 2013-12-03 2013-12-03
US61/911,214 2013-12-03
PCT/US2014/067117 WO2015084622A1 (en) 2013-12-03 2014-11-24 Methods of manufacturing benzoquinoline compounds

Publications (3)

Publication Number Publication Date
JP2017501141A JP2017501141A (ja) 2017-01-12
JP2017501141A5 true JP2017501141A5 (enExample) 2018-01-11
JP6542222B2 JP6542222B2 (ja) 2019-07-10

Family

ID=53264424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536571A Active JP6542222B2 (ja) 2013-12-03 2014-11-24 ベンゾキノリン化合物の製造方法

Country Status (14)

Country Link
US (8) US20150152099A1 (enExample)
EP (2) EP3076970A4 (enExample)
JP (1) JP6542222B2 (enExample)
KR (1) KR102391134B1 (enExample)
CN (1) CN105873589B (enExample)
AU (4) AU2014357518A1 (enExample)
BR (1) BR112016012747B1 (enExample)
CA (1) CA2930744A1 (enExample)
EA (2) EA032920B1 (enExample)
HK (1) HK1224222A1 (enExample)
IL (1) IL245539B (enExample)
MX (1) MX369956B (enExample)
NZ (1) NZ720301A (enExample)
WO (1) WO2015084622A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
DK3265085T3 (da) 2015-03-06 2022-10-03 Auspex Pharmaceuticals Inc Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
WO2017182916A1 (en) 2016-04-22 2017-10-26 Lupin Limited Novel process for preparation of tetrabenazine and deutetrabenazine
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
JP2020508337A (ja) 2017-02-27 2020-03-19 サンド・アクチエンゲゼルシヤフト バルベナジン塩の結晶形態
JP7608050B2 (ja) 2017-03-15 2025-01-06 オースペックス ファーマシューティカルズ インコーポレイテッド デューテトラベナジンの類似体、その調製及び使用
WO2019130252A2 (en) * 2017-12-29 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing deutetrabenazine
US11505549B2 (en) * 2018-02-01 2022-11-22 Lakshmi Prasad ALAPARTHI Process for preparation of Deutetrabenazine
CN112930214B (zh) 2018-10-18 2025-05-16 肿瘤多肽创新股份公司 含氘化合物
WO2020086765A1 (en) * 2018-10-24 2020-04-30 Neurocrine Biosciences, Inc. Processes for preparing a vmat2 inhibitor
CN111960999B (zh) * 2020-07-20 2021-11-02 暨明医药科技(苏州)有限公司 一种丁苯那嗪中间体的合成方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2326643A (en) 1941-08-20 1943-08-10 Rohm & Haas Complex polyamino sulphur compound
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999095A (en) * 1961-02-21 1965-07-21 Wellcome Found The preparation of quinolizine derivatives
HU175890B (en) 1977-06-15 1980-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 1,2,3,4,6,7-hexahydro-11-b-alpha-benzo-square bracket-a-square brecket closed-quinolyzine derivatives
US4316897A (en) 1980-09-10 1982-02-23 Hoffmann-La Roche Inc. Method of lowering serum prolactin
DE3407955A1 (de) 1984-03-03 1985-09-05 Dr. Karl Thomae Gmbh, 7950 Biberach Arzneimittel, enthaltend quartaere 3,4-dihydroisochinoliniumsalze
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9817028D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
EP1134290A3 (en) 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
PL1638529T3 (pl) 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
JP2007512338A (ja) 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション L型カルシウムチャンネルブロッカーとコリンエステラーゼ阻害剤を用いた組成物及び処置方法
US7367953B2 (en) 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
PL1856135T3 (pl) 2005-01-19 2010-05-31 Rigel Pharmaceuticals Inc Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie
AU2006261893A1 (en) 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20080033011A1 (en) 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
ME02508B (me) 2006-02-17 2017-06-20 Ratiopharm Gmbh Deuterisani derivati kateholamina i medikamenti koji obuhvataju pomenuta jedinjenja
TWI432214B (zh) 2006-05-02 2014-04-01 Univ Pennsylvania 經放射標記的二氫四苯那嗪(dihydrotetrabenazine)衍生物及其作為顯像劑的用途
HU227610B1 (en) 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
RU2463071C2 (ru) 2006-10-12 2012-10-10 Новартис Аг Применение модифицированных циклоспоринов
EP2081929B1 (en) * 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
US8163902B2 (en) 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20100204258A1 (en) 2007-03-12 2010-08-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
US7897768B2 (en) * 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
US9827210B2 (en) 2007-06-29 2017-11-28 Phovitreal Pty Ltd Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US7902364B2 (en) 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
WO2009124357A1 (en) 2008-04-10 2009-10-15 Malvin Leonard Eutick Fast dissolving oral formulations for critical drugs
US9012471B2 (en) 2008-04-11 2015-04-21 The Trustees Of Columbia University In The City Of New York Glucose metabolism modulating compounds
CN201204923Y (zh) 2008-04-14 2009-03-11 云南省烟草公司昆明市公司 鲜烟叶编叶机
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
DE102008040212A1 (de) 2008-07-07 2010-01-14 Zf Friedrichshafen Ag Radaufhängung für ein Fahrzeug
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
SI3061760T1 (en) 2008-09-18 2018-04-30 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
US20100113496A1 (en) 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル(バルバドス)エスアールエル 医薬組成物
JP4679658B2 (ja) 2009-10-10 2011-04-27 株式会社オーバル フィールド機器の光電センシング感度調整
CN102120742B (zh) 2010-01-08 2013-03-13 中国药科大学 一种丁苯那嗪的制备方法
WO2011106248A2 (en) 2010-02-24 2011-09-01 Auspex Pharmaceuticals, Inc. Trimethoxyphenyl inhibitors of tyrosine kinase
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
EP2576552A4 (en) 2010-06-01 2013-11-13 Aupex Pharmaceutical Inc BENZOQUINOLONE INHIBITORS OF VMAT2
WO2012006551A2 (en) 2010-07-08 2012-01-12 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
CN102260255B (zh) 2011-07-07 2013-07-10 江苏省原子医学研究所 一种9,10-二甲氧基-1,3,4,6,7,11b-六氢-3-异丁基-2H-苯并[a]喹嗪-2-酮的简便合成方法
US20130116215A1 (en) 2011-10-28 2013-05-09 Mireia Coma Combination therapies for treating neurological disorders
KR101362482B1 (ko) 2012-01-31 2014-02-12 한국과학기술연구원 테트라베나진과 다이하이드로테트라베나진의 제조방법
EP3884937A1 (en) 2012-03-23 2021-09-29 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN102936246A (zh) * 2012-11-08 2013-02-20 江苏暨明医药科技有限公司 丁苯那嗪的合成方法
EP2951178A4 (en) 2013-01-31 2016-07-06 Auspex Pharmaceuticals Inc VMAT2 INHIBITORS OF BENZOQUINOLONE TYPE
HK1221645A1 (zh) 2013-09-27 2017-06-09 Auspex Pharmaceuticals, Inc. Vmat2的苯并喹啉抑制剂
US20160303110A1 (en) 2013-11-22 2016-10-20 Auspex Pharmaceuticals, Inc. Methods of treating abnormal muscular activity
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CN105873589B (zh) 2013-12-03 2019-11-01 奥斯拜客斯制药有限公司 制造苯并喹啉化合物的方法
CA2936823A1 (en) 2014-01-27 2015-07-30 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2

Similar Documents

Publication Publication Date Title
JP2017501141A5 (enExample)
WO2014043706A8 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
CN103772278A (zh) 一种重要四氢异喹啉衍生物中间体及其合成方法
AR107633A1 (es) Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
JP2015078201A5 (enExample)
JP2015532645A5 (enExample)
RU2016135762A (ru) Способ получения (r)-1,1,3-триметил-4-аминоиндана
MX2017012184A (es) Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo.
JP2018507858A5 (enExample)
AR090566A1 (es) Proceso para la produccion de inhibidores de crr
JP2013531058A5 (enExample)
AR071744A1 (es) Proceso para la preparacion de 6-sustituido-1-(2h)-isoquinolinonas, intermediarios para su sintesis y metodos de obtencion de estos intermediarios.
EA201690755A1 (ru) Солевые и кристаллические формы ингибитора plk-4
CN102659672B (zh) 高纯度苯磺酸左旋氨氯地平的制备方法
EA201990236A1 (ru) Новые способы получения стимуляторов растворимой гуанилатциклазы
EA201990237A1 (ru) Новые способы получения стимуляторов растворимой гуанилатциклазы
RU2014126489A (ru) Способ извлечения налмефена гидрохлорида
HRP20191632T1 (hr) Kemijski postupak dobivanja spiroindolona i njihovih međuprodukata
RU2016148181A (ru) Способ получения оптически активных энантиомеров пирлиндола и его солей
BR112016024977A2 (pt) processo para a preparação de polimorfos de imidacloprida
WO2016104960A3 (ko) 결정성 페북소스타트 피돌레이트 염 및 이의 제조 방법
CN101037411B (zh) 一种四氢异喹啉外消旋体的拆分方法
EA202090197A1 (ru) Способ получения тапентадола и его промежуточных соединений
CN103965108B (zh) 一种合成劳丹宁的方法
WO2016157065A3 (en) A process for preparation of dexmethylphenidate hydrochloride